AN2 Therapeutics, Inc. Contracts & Agreements
25 Contracts & Agreements
- Business Finance (6 contracts)
- Human Resources (8)
- Intellectual Property (2)
- Uncategorized (9)
- Rights Agreement, dated as of August 15, 2024, between AN2 Therapeutics, Inc. and Equiniti Trust Company, LLC, which includes the Form of Certificate of Designations of Series A... (Filed With SEC on August 19, 2024)
- Non-Employee Director Compensation Policy (Filed With SEC on May 14, 2024)
- AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan (Filed With SEC on March 29, 2024)
- Form of Restricted Stock Unit Grant Notice and Award Agreement under the AN2 Therapeutics, Inc. 2022 Equity Incentive Plan (Filed With SEC on March 29, 2024)
- AN2 Therapeutics, Inc. 2022 Equity Incentive Plan (Filed With SEC on March 29, 2024)
- Underwriting Agreement, between the Company, Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C., dated as of August 15, 2023 (Filed With SEC on August 16, 2023)
- Offer Letter by and between the Registrant and Joshua Eizen, dated September 19, 2022 (Filed With SEC on November 9, 2022)
- Form of Common Stock Certificate (Filed With SEC on March 21, 2022)
- Form of Underwriting Agreement (Filed With SEC on March 21, 2022)
- Offer Letter by and between the Registrant and Sanjay Chanda, dated November 19, 2019 (Filed With SEC on March 4, 2022)
- Amended and Restated Global Health Agreement by and among the Registrant, Adjuvant Global Health Technology Fund L.P., and Adjuvant Global Health Technology Fund DE L.P., dated... (Filed With SEC on March 4, 2022)
- License Agreement by and between the Registrant and Brii Biosciences Limited, dated November 20, 2019 (Filed With SEC on March 4, 2022)
- License Agreement by and between the Registrant and Anacor Pharmaceuticals, Inc., dated November 20, 2019, as amended on December 3, 2021 (Filed With SEC on March 4, 2022)
- Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated March 5, 2020 (Filed With SEC on March 4, 2022)
- Offer Letter by and between the Registrant and Lucy Day, dated November 19, 2019 (Filed With SEC on March 4, 2022)
- Offer Letter by and between the Registrant and Eric Easom, dated November 19, 2019 (Filed With SEC on March 4, 2022)
- Form of Indemnity Agreement by and between the Registrant and its directors and executive officers (Filed With SEC on March 4, 2022)
- AN2 Therapeutics, Inc. Officer Severance Plan (Filed With SEC on March 4, 2022)
- AN2 Therapeutics, Inc. 2022 Non-Employee Director Compensation Policy (Filed With SEC on March 4, 2022)
- AN2 Therapeutics, Inc. 2022 Employee Stock Purchase Plan (Filed With SEC on March 4, 2022)
- Forms of Restricted Stock Unit Grant Notice and Award Agreement under the AN2 Therapeutics, Inc. 2022 Equity Incentive Plan (Filed With SEC on March 4, 2022)
- Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the AN2 Therapeutics, Inc. 2022 Equity Incentive Plan (Filed With SEC on March 4, 2022)
- AN2 Therapeutics, Inc. 2022 Equity Incentive Plan (Filed With SEC on March 4, 2022)
- Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise and Early Exercise Stock Purchase Agreement under the AN2 Therapeutics, Inc. 2017 Equity... (Filed With SEC on March 4, 2022)
- AN2 Therapeutics, Inc. 2017 Equity Incentive Plan, as amended (Filed With SEC on March 4, 2022)
